Provided by Tiger Trade Technology Pte. Ltd.

Avalyn Pharma

38.37
+1.243.34%
Post-market: 38.370.00000.00%19:30 EDT
Volume:159.50K
Turnover:6.13M
Market Cap:1.70B
PE:-16.47
High:39.68
Open:37.13
Low:37.06
Close:37.13
52wk High:40.17
52wk Low:24.15
Shares:44.33M
Float Shares:16.67M
Volume Ratio:0.93
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3300
EPS(LYR):-87.7434
ROE:-68.34%
ROA:-41.74%
PB:4.27
PE(LYR):-0.44

Loading ...

Company Profile

Company Name:
Avalyn Pharma
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
55
Office Location:
105 W First Street,Boston,Massachusetts,United States
Zip Code:
02127
Fax:
- -
Introduction:
Avalyn Pharma Inc. was incorporated in the state of Delaware on May 27, 2011. The company is a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases, including progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, and other interstitial lung diseases.

Directors

Name
Position
Lyn Baranowski
Chief Executive Officer,Director and President
David Friedman
Independent Director
Erin Lavelle
Independent Director
Heather Turner
Board Chair and Director
Jill Carroll
Independent Director
Jon Congleton
Independent Director
Kate Haviland
Independent Director

Shareholders

Name
Position
Lyn Baranowski
Chief Executive Officer,Director and President
Melissa Rhodes
Chief Operating Officer
Douglas Carlson
Chief Business Officer and Chief Financial Officer
Adam Golden
General Counsel
Howard M. Lazarus
Chief Medical Officer